1) 長瀬洋之. 専門医のためのアレルギー学講座 免疫・アレルギー疾患の分子標的 喘息における分子標的薬の可能性. アレルギー. 2015 ; 64 : 14-22.
2) Nagase H, Adachi M, Matsunaga K, et al. Prevalence, disease burden, and treatment reality of patients with severe, uncontrolled asthma in Japan. Allergol Int. 2019.
3) Nagase H. Severe asthma in Japan. Allergol Int. 2019 ; 68 (2) : 167-71.
4) Leckie MJ, Brinke At, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. The Lancet. 2000 ; 356 : 2144-8.
5) 日本呼吸器学会, 日本アレルギー学会. 成人気管支喘息における生物学的製剤の適正使用ステートメント. 2020.
6) Bousquet J, Rabe K, Humbert M, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med. 2007 ; 101 : 1483-92.
7) Hanania NA, Wenzel S, Rosen K, et al. Exploring the effects of omalizumab in allergic asthma : an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013 ; 187 : 804-11.
8) Casale TB, Luskin AT, Busse W, et al. Omalizumab effectiveness by biomarker status in patients with asthma : evidence from PROSPERO, a prospective real-world study. J Allergy Clin Immunol Praet. 2019 ; 7 : 156-64. e1.
9) Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014 ; 371 : 1198-207.
10) Nagase H, Ueki S, Fujieda S. The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases : asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis. Allergol Int. 2020 ; 69 : 178-86.
11) Nagase H, Okugawa S, Ota Y, et al. Expression and function of toll-like receptors in eosinophils : activation by toll-like receptor 7 ligand. J Immunol. 2003 ; 171 : 3977-82.
12) Khatri S, Moore W, Gibson PG, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2019 ; 143 : 1742-51.
13) Busse WW, Bleecker ER, FitzGerald JM, et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma : 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2019 ; 7 : 46-59.
14) Bleecker ER, Wechsler ME, FitzGerald JM, et al. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur Respir J. 2018 ; 52 : 1800936.
15) Ortega HG, Yancey SW, Mayer B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds : a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016 ; 4 : 549-56.
16) FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA) : a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016 ; 388 : 2128-41.
17) Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO) : a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016 ; 388 : 2115-27.
18) Chipps BE, Newbold P, Hirsch I, et al. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma. Ann Allergy Asthma Immunol. 2018 ; 120 : 504-11. e4.
19) Yancey SW, Keene ON, Albers FC, et al. Biomarkers for severe eosinophilic asthma. J Allergy Clin immunol. 2017 ; 140 : 1509-18.
20) Flood-Page PT, Menzies-Gow AN, Kay AB, et al. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. 2003 ; 167 : 199-204.
21) Laviolette M, Gossage DL, Gauvreau G, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013 ; 132 : 1086-96. e5.
22) Sridhar S, Liu H, Pham TH, et al. Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases. Respir Res. 2019 ; 20 : 14.
23) Busse W, Chupp G, Nagase H, et al. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds : Indirect treatment comparison. J Allergy Clin Immunol. 2019 ; 143 : 190-200. e20.
24) Bourdin A, Husereau D, Molinari N, et al. Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma : a systematic review. Eur Respir J. 2018 ; 52 : 1801393.
25) Kurosawa M, Sutoh E. Severe uncontrolled eosinophilic asthma, which responded to benralizumab after failure to respond to mepolizumab. Ann Allergy Asthma Immunol. 2019 ; 122 : 431-3.
26) Matsuno O, Minamoto S. Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab. Respir Med Case Rep. 2019 ; 28 : 100899.
27) Mesnil C, Raulier S, Paulissen G, et al. Lung-resident eosinophils represent a distinct regulatory eosinophil subset. J Clin Invest. 2016 ; 126 : 3279-95.
28) Fujisawa T, Kato Y, Nagase H, et al. Chemokines induce eosinophil degranulation through CCR-3. J Allergy Clin Immunol. 2000 ; 106 : 507-13.
29) Komiya A, Nagase H, Yamada H, et al. Concerted expression of eotaxin-1, eotaxin-2, and eotaxin-3 in human bronchial epithelial cells. Cell Immunol. 2003 ; 225 : 91-100.
30) Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018 ; 378 : 2486-96.
31) Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014 ; 371 : 1189-97.
32) Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017 ; 376 : 2448-58.
33) Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018 ; 378 : 2475-85.
34) 三好昭暉, 小泉佑太, 小林このみ, 他. 気管支喘息 (成人) : 生物学的製剤 (その他) 重症喘息における4種の分子標的薬の適応症例の比率と臨床背景の比較. アレルギー. 2019 ; 68 : 523.
35) Bousquet J, Brusselle G, Buhl R, et al. Care pathways for the selection of a biologic in severe asthma. Eur Respir J. 2017 ; 50 : 1701782.
36) 日本呼吸器学会. 難治性喘息診断と治療の手引き 2019. 東京 : メディカルビュー社.
37) Furuta S, Iwamoto T, Nakajima H. Update on eosinophilic granulomatosis with polyangiitis. Allergol Int. 2019 ; 68 : 430-6.
38) Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017 ; 376 : 1921-32.
39) Mohammad AJ, Hot A, Arndt F, et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Ann Rheum Dis. 2016 ; 75 : 396-401.
40) Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016 ; 375 : 2335-48.
41) 厚生労働省. 最適使用推進ガイドライン デュピルマブ (遺伝子組換え) (販売名 : デュピクセント皮下注 300 mg シリンジ) ~アトピー性皮膚炎~. 2018.
42) Okubo K, Okano M, Sato N, et al. Add-on omalizumab for inadequately controlled severe pollinosis despite standard-of-care : a randomized study. J Allergy Clin Immunol Pract. 2020 ; 8 : 3130-40.
43) 厚生労働省. 最適使用推進ガイドライン オマリズマブ (遺伝子組換え) (販売名 : ゾレア皮下注用 75 mg, ゾレア皮下注用 150 mg, ゾレア 皮下注 75 mg シリンジ, ゾレア皮下注 150 mg シリンジ) ~季節性アレルギー性鼻炎~. 2019.
44) Maurer M, Rosen K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013 ; 368 : 924-35.
45) Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52) : results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019 ; 394 : 1638-50.
46) 厚生労働省. 最適使用推進ガイドライン デュピルマブ (遺伝子組換え) (販売名 : デュピクセント皮下注 300 mg シリンジ) ~鼻茸を伴う慢性副鼻腔炎~. 2020.